Listen
BRUKINSA (zanubrutinib) - Follicular lymphoma (FL)
Opinions on drugs -
Posted on
Jul 26 2024
Reason for request
Indication extension
Summary of opinion
Unfavourable opinion for reimbursement in the indication “BRUKINSA in combination with obinutuzumab is indicated for the treatment of adult patients with refractory or relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies”.
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BRUKINSA (zanubrutinib) is insufficient to justify public funding cover in the MA indication in view of the available alternatives. |
Clinical Added Value
| Not applicable |
